These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 11574898

  • 1. In human therapy, is the drug-drug interaction or the adverse drug reaction the issue?
    du Souich P.
    Can J Clin Pharmacol; 2001; 8(3):153-61. PubMed ID: 11574898
    [Abstract] [Full Text] [Related]

  • 2. Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events and drug-drug interactions.
    Tulner LR, Kuper IM, Frankfort SV, van Campen JP, Koks CH, Brandjes DP, Beijnen JH.
    Am J Geriatr Pharmacother; 2009 Apr; 7(2):93-104. PubMed ID: 19447362
    [Abstract] [Full Text] [Related]

  • 3. Paediatric adverse drug reaction reporting: understanding and future directions.
    Carleton BC, Smith MA, Gelin MN, Heathcote SC.
    Can J Clin Pharmacol; 2007 Apr; 14(1):e45-57. PubMed ID: 17297195
    [Abstract] [Full Text] [Related]

  • 4. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T, Price A.
    Am Fam Physician; 2007 Aug 01; 76(3):391-6. PubMed ID: 17708140
    [Abstract] [Full Text] [Related]

  • 5. Drug interactions: keeping it straight.
    Anastasio GD, Cornell KO, Menscer D.
    Am Fam Physician; 1997 Sep 01; 56(3):883-8, 891-4. PubMed ID: 9301579
    [Abstract] [Full Text] [Related]

  • 6. Characteristics and quality of adverse drug reaction reports by pharmacists in Norway.
    Gedde-Dahl A, Harg P, Stenberg-Nilsen H, Buajordet M, Granas AG, Horn AM.
    Pharmacoepidemiol Drug Saf; 2007 Sep 01; 16(9):999-1005. PubMed ID: 17457794
    [Abstract] [Full Text] [Related]

  • 7. [Role of cytochrome P450 enzymes in pharmaceutical preparations].
    Baede van Dijk PA, de Graeff PA, Lekkerkerker JF.
    Ned Tijdschr Geneeskd; 1999 Dec 25; 143(52):2607-11. PubMed ID: 10633805
    [Abstract] [Full Text] [Related]

  • 8. Potential drug interactions and duplicate prescriptions among cancer patients.
    Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK.
    J Natl Cancer Inst; 2007 Apr 18; 99(8):592-600. PubMed ID: 17440160
    [Abstract] [Full Text] [Related]

  • 9. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
    Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT, Kwaan HC, Bennett CL.
    J Clin Oncol; 2003 Oct 15; 21(20):3859-66. PubMed ID: 14551305
    [Abstract] [Full Text] [Related]

  • 10. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics.
    Bender S, Grohmann R, Engel RR, Degner D, Dittmann-Balcar A, Rüther E.
    Pharmacopsychiatry; 2004 Mar 15; 37 Suppl 1():S46-53. PubMed ID: 15052514
    [Abstract] [Full Text] [Related]

  • 11. Drug interactions in the elderly.
    Kurfees JF, Dotson RL.
    J Fam Pract; 1987 Nov 15; 25(5):477-88. PubMed ID: 3681207
    [Abstract] [Full Text] [Related]

  • 12. [Adverse effects and drug interactions].
    Perlík F.
    Cas Lek Cesk; 2004 Nov 15; 143(2):110-3. PubMed ID: 15077574
    [Abstract] [Full Text] [Related]

  • 13. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms.
    Wijnen PA, Op den Buijsch RA, Drent M, Kuijpers PM, Neef C, Bast A, Bekers O, Koek GH.
    Aliment Pharmacol Ther; 2007 Dec 15; 26 Suppl 2():211-9. PubMed ID: 18081664
    [Abstract] [Full Text] [Related]

  • 14. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective.
    Tremlett HL, Oger J.
    Mult Scler; 2008 Jan 15; 14(1):94-105. PubMed ID: 17881392
    [Abstract] [Full Text] [Related]

  • 15. Drug interactions with the nonsedating antihistamines.
    Ament PW, Paterson A.
    Am Fam Physician; 1997 Jul 15; 56(1):223-31. PubMed ID: 9225677
    [Abstract] [Full Text] [Related]

  • 16. Metabolic drug interactions with newer antipsychotics: a comparative review.
    Spina E, de Leon J.
    Basic Clin Pharmacol Toxicol; 2007 Jan 15; 100(1):4-22. PubMed ID: 17214606
    [Abstract] [Full Text] [Related]

  • 17. [Adverse drug reactions definitions and terminology].
    Rabinovitz H, Berkowitch M, Golik A, Shani S.
    Harefuah; 2001 Dec 15; 140(12):1181-6, 1228. PubMed ID: 11789305
    [Abstract] [Full Text] [Related]

  • 18. Under-reporting of serious adverse drug reactions in Sweden.
    Bäckström M, Mjörndal T, Dahlqvist R.
    Pharmacoepidemiol Drug Saf; 2004 Jul 15; 13(7):483-7. PubMed ID: 15269932
    [Abstract] [Full Text] [Related]

  • 19. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
    Wolzt M, Sarich TS, Eriksson UG.
    Semin Vasc Med; 2005 Aug 15; 5(3):254-8. PubMed ID: 16123912
    [Abstract] [Full Text] [Related]

  • 20. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management.
    Sokol KC, Knudsen JF, Li MM.
    J Clin Pharm Ther; 2007 Apr 15; 32(2):169-75. PubMed ID: 17381667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.